CompanyGraph
Kenvue Inc.
KVUE · NYSE Arca · United States
Makes Tylenol, Benadryl, Listerine, and Neutrogena inside factories that must satisfy two different sets of FDA rules at once.
Kenvue makes over-the-counter medicines and personal care products — Tylenol, Benadryl, Listerine, Neutrogena — out of manufacturing sites that must simultaneously satisfy two separate FDA frameworks: drug Good Manufacturing Practice rules for the acetaminophen and ibuprofen lines, and cosmetic stability standards for the mouthwash and skincare lines. Maintaining both compliance systems in parallel is expensive enough that it only makes financial sense if a company already earns revenue across both categories, so a competitor selling only pain relief or only skincare would have to absorb the full cost of a dual regulatory infrastructure before it could match Kenvue's shelf presence. Because retail availability for products like Tylenol cannot lapse — shoppers who find an empty shelf once will find a substitute — any FDA enforcement action that suspends a registered facility stops revenue across every brand that facility supports. The same compliance overlap that protects Kenvue from new entrants also concentrates its risk: a manufacturing violation found on the drug side of a site invites FDA scrutiny of the cosmetic lines running in the same building, so a single quality failure can put the entire portfolio at that facility under regulatory pressure at once.
How does this company make money?
Kenvue sells products by the unit to pharmacy chains and retail distributors, and it pays those chains promotional fees to secure favorable shelf placement. It also sells directly to consumers through e-commerce. Larger retail customers get lower prices per unit in exchange for buying in higher volumes.
What makes this company hard to replace?
Doctors and pediatricians recommend specific brand names — Tylenol, Listerine — by name in clinical settings, which makes patients reluctant to try something else. Pediatrician offices distribute Johnson's baby product samples and branded recommendation cards, so many parents bond to those products before they have even shopped for themselves. Pharmacy shelf placement deals with CVS and Walgreens also mean Kenvue's products are physically positioned where shoppers habitually reach, making a competing brand harder to notice.
What limits this company?
Every product formula needs its own approval process — stability testing, regulatory filings, shelf-life records — before it can be sold. And a factory's compliance history belongs to that factory; it cannot be copied or transferred to a new site. So if a registered factory is suspended, Kenvue cannot quickly move its production or its regulatory standing somewhere else.
What does this company depend on?
Kenvue cannot operate without chemical manufacturers that supply the active ingredients for its pain relievers and antihistamines, valid FDA facility registrations for its factories across multiple countries, functioning Good Manufacturing Practice compliance systems at each site, retail distribution agreements with CVS and Walgreens, and trademark licenses for names like Tylenol and Neutrogena that it received when it was spun off from Johnson & Johnson.
Who depends on this company?
CVS and Walgreens pharmacies would lose their core over-the-counter inventory for pain relief and allergy treatment if Kenvue stopped producing. Pediatricians who hand out Johnson's baby product samples and recommendation cards to new parents would have nothing to give. Dental professionals who recommend Listerine to patients after procedures would lose their go-to option.
How does this company scale?
Manufacturing more units is relatively straightforward — formulation recipes and quality-control procedures can be standardized and copied across additional production lines. What does not scale easily is regulatory compliance: every new country Kenvue enters requires its own product registrations, clinical data submissions, and factory inspections, each of which demands specialized regulatory staff and cannot be rushed or automated.
What external forces can significantly affect this company?
When a manufacturing quality scandal hits the pharmaceutical industry broadly, the FDA tends to inspect all makers more often, which raises compliance costs for Kenvue even if it did nothing wrong. Aging populations in wealthier countries are pushing up demand for pain relief and digestive health products, which is a tailwind. At the same time, currency swings in the countries where Kenvue's factories operate can raise the cost of imported active ingredients without any warning.
Where is this company structurally vulnerable?
If the FDA finds a manufacturing violation at one of Kenvue's factories — whether the problem is on the drug line or the cosmetic line — the agency gains the authority to inspect everything at that site. A single finding can produce warning letters or forced product withdrawals that reach across every brand running through that factory, from Tylenol to Neutrogena.